Cover Image

FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group

High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current trial eval...

Full description

Saved in:
Bibliographic Details
Main Authors: Hofheinz, Ralf-Dieter (Author) , Merx, Kirsten (Author) , Haag, Georg Martin (Author) , Springfeld, Christoph (Author) , Ettrich, Thomas (Author) , Borchert, Kersten (Author) , Kretzschmar, Albrecht (Author) , Teschendorf, Christian (Author) , Siegler, Gabriele (Author) , Ebert, Matthias (Author) , Goekkurt, Eray (Author) , Mahlberg, Rolf (Author) , Homann, Nils (Author) , Pink, Daniel (Author) , Bechstein, Wolf (Author) , Reichardt, Peter (Author) , Flach, Hagen (Author) , Gaiser, Timo (Author) , Battmann, Achim (Author) , Oduncu, Fuat S. (Author) , Loose, Maria (Author) , Sookthai, Disorn (Author) , Pauligk, Claudia (Author) , Göetze, Thorsten O. (Author) , Al-Batran, Salah-Eddin (Author)
Format: Article (Journal)
Language:English
Published: June 16, 2022
In: Journal of clinical oncology
Year: 2022, Volume: 40, Issue: 32, Pages: 3750-3761
ISSN:1527-7755
DOI:10.1200/JCO.22.00380
Online Access:Resolving-System, Volltext: https://doi.org/10.1200/JCO.22.00380
Verlag, Volltext: https://ascopubs.org/doi/10.1200/JCO.22.00380
Get full text
Author Notes:Ralf-Dieter Hofheinz, Kirsten Merx, Georg M. Haag, Christoph Springfeld, Thomas Ettrich, Kersten Borchert, Albrecht Kretzschmar, Christian Teschendorf, Gabriele Siegler, Matthias P. Ebert, Eray Goekkurt, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf Bechstein, Peter Reichardt, Hagen Flach, Timo Gaiser, Achim Battmann, Fuat S. Oduncu, Maria Loose, Disorn Sookthai, Claudia Pauligk, Thorsten O. Göetze, and Salah-Eddin Al-Batran
Description
Summary:High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current trial evaluates the addition of trastuzumab and pertuzumab to FLOT as perioperative treatment for human epidermal growth factor receptor 2-positive resectable EGA.
Item Description:Gesehen am 25.01.2023
Physical Description:Online Resource
ISSN:1527-7755
DOI:10.1200/JCO.22.00380

Similar Items